Clinical Trials

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Nasopharyngeal Carcinoma

NCT07303283 2026-03-05

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

218 enrolled

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

238 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT06976190 2026-01-20

Magic-C002

446 enrolled

Nasopharyngeal Carcinoma, Recurrence

NCT07331428 2026-01-09

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

25 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT07248670 2025-11-25

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

252 enrolled

Nasopharyngeal Carcinoma

NCT06987123 2025-05-23

TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

62 enrolled

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

NCT04517214 2025-04-02

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

100 enrolled

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

664 enrolled

Nasopharyngeal Carcinoma

NCT06629597 2025-02-10

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

400 enrolled

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT05869227 2024-12-30

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

166 enrolled

Nasopharyngeal Carcinoma

NCT06277050 2024-04-30

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

264 enrolled

Nasopharyngeal Carcinoma

NCT06331845 2024-03-26

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

39 enrolled

Nasopharyngeal Carcinoma

NCT06259721 2024-03-07

Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Recruiting

22 enrolled

Nasopharyngeal Carcinoma

NCT04072107 2023-06-18

EP-STAR

110 enrolled

Nasopharyngeal Carcinoma

NCT02940925 2023-04-12

TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma

Phase 3 Completed

241 enrolled

Nasopharyngeal Carcinoma

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma

NCT05717764 2023-02-08

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

500 enrolled

Nasopharyngeal Carcinoma

NCT02460419 2022-10-28

Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma

Phase 3 Completed

104 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT05514275 2022-08-24

Radiotherapy Combined With Endostatin and Capecitabine for NPC

Phase 2 Recruiting

41 enrolled

Nasopharyngeal Carcinoma

NCT05484375 2022-08-02

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

40 enrolled

Nasopharyngeal Carcinoma

NCT05201859 2022-05-06

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

150 enrolled

Nasopharyngeal Carcinoma

NCT05342792 2022-04-25

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

556 enrolled

Nasopharyngeal Carcinoma

NCT05290194 2022-04-14

Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

Phase 2 Recruiting

28 enrolled

Nasopharyngeal Carcinoma

NCT04220528 2020-01-07

Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC

129 enrolled

Nasopharyngeal Carcinoma

NCT00379262 2019-08-07

Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma

Phase 3 Completed

803 enrolled

Nasopharyngeal Carcinoma

NCT02958111 2019-06-12

CAN

406 enrolled

Phase 3 Not yet recruiting

Nasopharyngeal Carcinoma

NCT03503136 2018-05-11

NX-NPC

632 enrolled

Nasopharyngeal Carcinoma

NCT03427359 2018-02-09

Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Phase 2 Completed

65 enrolled

Nasopharyngeal Carcinoma

NCT02786641 2016-06-01

Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma

235 enrolled

Nasopharyngeal Carcinoma

NCT02360501 2016-04-20

Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma

Phase 2 Completed

50 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT02633176 2015-12-17

Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma

120 enrolled

Nasopharyngeal Carcinoma

NCT02621970 2015-12-04

Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma

534 enrolled

Nasopharyngeal Carcinoma

NCT00577057 2013-08-22

Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer

Phase NA Unknown

798 enrolled